Tenaya Therapeutics (TNYA) Price & Analysis

Compare

2,298 Followers

TNYA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.36 - $4.01

Previous CloseN/A

Volume1.07M

Average Volume (3M)3.60M

Market Cap

$176.01M

Enterprise Value$40.04M

Total Cash (Recent Filing)$71.67M

Total Debt (Recent Filing)$12.21M

Price to Earnings (P/E)―

Beta3.19

Next Earnings

Nov 05, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding162,976,100

10 Day Avg. Volume6,343,181

30 Day Avg. Volume3,596,634

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.23

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-19.21

Enterprise Value/Ebitda-0.43

Forecast

1Y Price Target

$10.14

Price Target Upside838.89% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical ProgressEncouragingly, DSMB reviews of data thus far have found no issues, and the company can continue to or start dosing at the higher dose in both programs.

Financial StabilityThe restructuring and workforce reduction plan should provide financial runway into the second half of 2026.

Research And DevelopmentTenaya is developing two AAV-based gene therapy approaches for the treatment of cardiomyopathies, which are expected to halt disease progression and improve symptoms after a single dose.

Bears Say

Clinical ChallengesIt remains complicated to discern whether the gene therapy is working due to varying levels of endogenous protein in patients.

Financial PerformanceTNYA reported a net loss of $23.3 million for the second quarter of 2025.

Tenaya Therapeutics News

Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)

“During the first half of 2025, we achieved target enrollment in our ongoing gene therapy clinical trials of...

22d ago

TNYA

Tenaya receives reviews from independent DSMB to advance TN-201, TN-401

Tenaya Therapeutics (TNYA) announced positive endorsements from each trial’s independent Data Safety and Monitoring Board, DSMB, to proceed...

29d ago

TNYA

Innovative Cardiac Gene Therapy Drives Buy Rating for Tenaya Therapeutics

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Tenaya Therapeutics yesterday and set a price target...

1d ago

TNYA

Innovative Cardiac Gene Therapy Advances: Tenaya Therapeutics’ Strategic Developments and Analyst Confidence

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target...

1d ago

TNYA

Innovative Gene Therapy Advancements: Tenaya Therapeutics’ Breakthrough in Protein Expression Measurement

William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating on...

2d ago

TNYA

Tenaya Therapeutics Reports Q2 2025 Financial Results

Tenaya Therapeutics, Inc. ( ($TNYA) ) has released its Q2 earnings. Here is a breakdown of the information...

14d ago

TNYA

Buy Rating for Tenaya Therapeutics: Financial Stability and Promising Clinical Trial Results

TD Cowen analyst Ritu Baral has maintained their bullish stance on TNYA stock, giving a Buy rating on...

18d ago

TNYA

Promising Developments and Strong Financial Position Drive Buy Rating for Tenaya Therapeutics

Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Tenaya Therapeutics and keeping the price target...

20d ago

TNYA

Promising Pipeline and Financial Prudence Drive Buy Rating for Tenaya Therapeutics

Leerink Partners analyst Mani Foroohar has reiterated their bullish stance on TNYA stock, giving a Buy rating yesterday....

20d ago

TNYA

Strong Financial Position and Promising Clinical Progress Drive Buy Rating for Tenaya Therapeutics

Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Tenaya Therapeutics and keeping the price target...

21d ago

TNYA

Buy Rating Affirmed for Tenaya Therapeutics Amid Promising Clinical Developments and Strong Financial Position

William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating on...

22d ago

TNYA

Promising Developments in Tenaya Therapeutics’ Clinical Trials Earn Buy Rating from Analyst

William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating today....

29d ago

TNYA

Tenaya Therapeutics announces it will present five abstracts as ASGCT 2025

Tenaya Therapeutics (TNYA) announced that it will present five abstracts at the upcoming American Society of Gene and...

4M ago

TNYA

Tenaya Therapeutics reports Q1 EPS (24c), consensus (20c)

“2025 is off to a strong start for Tenaya as we delivered positive data from our MyPEAK-1 clinical...

4M ago

TNYA

TNYA FAQ

What was Tenaya Therapeutics’s price range in the past 12 months?

Tenaya Therapeutics lowest stock price was $0.36 and its highest was $4.01 in the past 12 months.

What is Tenaya Therapeutics’s market cap?

Tenaya Therapeutics’s market cap is $176.01M.

When is Tenaya Therapeutics’s upcoming earnings report date?

Tenaya Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.

How were Tenaya Therapeutics’s earnings last quarter?

Tenaya Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.189 by $0.049.

Is Tenaya Therapeutics overvalued?

According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tenaya Therapeutics pay dividends?

Tenaya Therapeutics does not currently pay dividends.

What is Tenaya Therapeutics’s EPS estimate?

Tenaya Therapeutics’s EPS estimate is -0.15.

How many shares outstanding does Tenaya Therapeutics have?

Tenaya Therapeutics has 162,976,100 shares outstanding.

What happened to Tenaya Therapeutics’s price movement after its last earnings report?

Tenaya Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.189. Following the earnings report the stock price went down -1.493%.

Which hedge fund is a major shareholder of Tenaya Therapeutics?

Currently, no hedge funds are holding shares in TNYA

Tenaya Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-85.21%

Trailing 12-Months

Asset Growth

-25.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tenaya Therapeutics

Tenaya Therapeutics (TNYA) is a biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease. The company operates within the biopharmaceutical sector and is committed to advancing a pipeline of novel therapies aimed at addressing the underlying causes of various forms of heart disease through gene therapy, cellular regeneration, and precision medicine approaches.

Tenaya Therapeutics (TNYA) Earnings & Revenues

Historic Earnings Reports

TNYA Stock 12 Month Forecast

Average Price Target

$10.14

▲(838.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","41":"$41","-1":"-$1","9.5":"$9.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,9.5,20,30.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,3.695384615384615,6.72076923076923,9.746153846153845,12.77153846153846,15.796923076923076,18.822307692307692,21.847692307692306,24.873076923076923,27.89846153846154,30.923846153846153,33.949230769230766,36.97461538461538,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,1.3984615384615386,2.126923076923077,2.855384615384615,3.583846153846154,4.312307692307693,5.0407692307692304,5.769230769230769,6.497692307692308,7.226153846153847,7.954615384615385,8.683076923076923,9.411538461538461,{"y":10.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.8492307692307692,1.0284615384615385,1.2076923076923078,1.3869230769230771,1.5661538461538465,1.7453846153846153,1.9246153846153846,2.103846153846154,2.2830769230769232,2.4623076923076925,2.641538461538462,2.8207692307692307,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.37,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >